Droplet® US – FOR HEALTH |

FOR HEALTH-CARE PROFESSIONALS DROPLET® US

Diabetes is a global epidemic affecting an estimated 422 million people worldwide.
WHO projects diabetes will be the 7th leading cause of death by 2030.
An estimated 4 million people die annually from diabetes complications.

Taking insulin is often part of treating diabetes. Sterile, single-use HTL-STREFA PEN NEEDLES are intended to be used with a pen injector device for the subcutaneous injection of insulin. They are commonly used by people with diabetes who often require multiple daily insulin injections.

Learn more about Droplet pen needles

Many people with diabetes still find injecting of insulin as an unpleasant and painful process which may cause poor disease control. The proper injection technique helps diabetic patients to achieve the best possible health outcomes by ensuring that the correct dose of medication is delivered to the correct injection site, using the correct needle size.

Droplet pen needles proactively address:

easy adjustment and use
greater convenience
insulin delivery precision
compatible with most of the available pen injectors

Layer_10

Droplet® pen needles are available in 10 versions, each marked with a different
color for easier identification

* Available on US and Canada markets only.

Remember!
Pen needles should be used only once and dispose!

Sterility is guaranteed if the needle seal is unbroken. The tip of the needle may be damaged with reuse.
This can increase the chance of experiencing pain when injecting as the needle tip is dulled; used needles also increase infection risk and cause possible needle clogging and inaccurate dosing.

Re-usage can:

lead to needle breakage (1)
cause lipohypertrophy (2)
dull or bend the tip causing bleeding, bruising, or scarring (3)
increase the risk of the needle breaking off in the skin (1)
increase the risk of infection because the needle is no longer sterile (4)

Sources:
(1) www.diabetes.co.uk; www.diabetes.co.uk/insulin/reusing-insulin-pen-needles.html
(2) McNally P, Jowet N, Kurinczuk J, Peck R, Hearnshaw J. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulin, Postgrad. Med. 64(1988) 850–853.
(3) Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016 Sep;91(9):1231-55
(4) American Diabetes Association. Insulin administration. Diabetes Care. 2004;26(Suppl 1):S121–S124